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Abstract
Depression is highly prevalent among HIV-infected patients, yet little is known about the quality of HIV
providers’ depression treatment practices. We assessed depression treatment practices of 72 HIV providers at
three academic medical centers in 2010–2011 with semi-structured interviews. Responses were compared to
national depression treatment guidelines. Most providers were confident that their role included treating de-
pression. Providers were more confident prescribing a first antidepressant than switching treatments. Only 31%
reported routinely assessing all patients for depression, 13% reported following up with patients within 2 weeks
of starting an antidepressant, and 36% reported systematically assessing treatment response and tolerability in
adjusting treatment. Over half of providers reported not being comfortable using the full FDA-approved dosing
range for antidepressants. Systematic screening for depression and best-practices depression management were
uncommon. Opportunities to increase HIV clinicians’ comfort and confidence in treating depression, including
receiving treatment support from clinic staff, are discussed.
Introduction
Depression is a common condition in people living withHIV/AIDS, with prevalence ranging from 20% to
30%.1,2 Despite its high prevalence, depression is commonly
underdiagnosed and undertreated in this population.3 The
under-recognition of depression among people living with
HIV/AIDS not only leads to ongoing psychiatric morbidity,
but can also contribute to higher sexual and injection drug
use risk behaviors, poor antiretroviral (ARV) adherence, and
worse clinical outcomes.4,5 Although the burden of depres-
sion is high, access to specialty mental health care for this
largely disenfranchised and uninsured population may be
limited. HIV providers, who often serve as primary care
providers to their patients, frequently play an important role
in identification and management of depression, especially
given increasing emphasis on ‘‘medical home’’ models for
HIV care.6
Although the importance of depression and depression
management for HIV clinical care has been long recognized,
little is known about the quality or the extent of depression
care that is provided by HIV clinicians. Two decades of re-
search and policy initiatives have focused on integrating de-
pression management into primary care practice, and
convincing evidence has demonstrated the capacity of non-
psychiatric providers to deliver quality depression care, es-
pecially through use of decision support and collaborative
care models.7,8 Such models generally deploy nonprescribing
‘‘care managers’’ with expertise in depression management
who follow evidence-based guidelines to advise nonpsychi-
atric providers in identifying depression and managing
treatment.9 Similar efforts in medical settings for chronically
ill patient populations (e.g., diabetes, cardiovascular, or HIV
patients) are at an earlier stage of development. In order to
assess the potential of such models to improve the capacity for
and quality of depression care within HIV clinical settings, an
evaluation is warranted of the current status of depression
care including HIV providers’ attitudes toward providing
depression care and current practices relating to identifying
and treating depression.
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This article aims to describe HIV medical providers’ atti-
tudes and practices toward diagnosing, treating, and man-
aging depression in HIV clinical settings and to compare
current practices to national evidence-based depression
treatment guidelines.
Methods
Participating sites were outpatient Infectious Diseases
clinics at three academic medical centers, each of which
serves > 1500 HIV-infected patients, during preparation for a
multisite randomized controlled trial of a depression treat-
ment intervention (SLAM DUNC Study, R01MH086362). The
three sites have similar patient populations whose charac-
teristics (approximately two-thirds African American, with
the remainder primarily non-Hispanic White; approximately
two-thirds male; patients primarily in their 30s and 40s, and
primarily infected through male-to-male or heterosexual
sexual contact) are reflective of the HIV epidemic in the US
South. All providers of direct HIV medical care at the three
sites were eligible for participation. In-person, semi-
structured interviews were conducted by trained staff at each
site. The data presented in this article were collected prior to
the launch of randomized controlled trial activities at each site
(2010 for sites 1 and 2; 2011 for site 3). All study activities were
approved by the Institutional Review Boards at the respective
sites. All participating providers gave written informed con-
sent. Each interview was either audio-recorded and tran-
scribed, or summarized by research personnel during the
interview.
Descriptive information about each provider (race,
gender, years of clinical experience, and caseload) was
collected. Providers were asked to estimate the proportion
of their HIV patient caseload that was depressed and the
proportion that was receiving treatment for depression. A
series of questions assessed providers’ comfort with and
attitudes toward treating depression in their HIV patients,
with responses measured on Likert scales. Finally, open-
ended questions asked about providers’ current depression
treatment practices: how they identify depression, make
decisions around treatment initiation, adjust antidepres-
sant treatment to account for interactions with ARV and
other medications, assess response to treatment, make
decisions around treatment adjustment, and maintain
treatment. Interviews were conducted by an interviewer
with a graduate-level education.
Definition of best-practices standards
In order to define best practices for depression treatment,
two psychiatrists with expertise in evidence-based manage-
ment of depression ( JA, BNG) reviewed general depression
treatment guidelines published by the American Psychiatric
Association and HIV-specific guidelines published by the
New York State Department of Health.10,11 This review yiel-
ded nine core principles of best-practices pharmacological
treatment of depression: eight principles applicable to all
populations and one principle specific to HIV-infected pa-
tients taking ARV therapy. These principles are summarized
in Table 1.
Analysis
We described provider and caseload characteristics and
providers’ confidence in treating depression using medians
and interquartile ranges (due to skewed distributions of
some continuous variables) or proportions. We used quan-
titative and qualitative methods to describe the degree of
conformity of providers’ self-reported depression treatment
practices with evidence-based guidelines. A psychiatrist
( JA) assigned providers a score for each of the nine best-
practices principles based on providers’ responses to the
open-ended questions about their current practices, with a
higher score indicating closer concordance with evidence-
based practice (Table 2). To analyze the qualitative data, we
utilized content analysis12 to identify themes related to each
of the nine indicators of depression treatment practice
(Table 1). Two co-authors (KB, MW) reviewed the
Table 1. Best Practices Framework: Adapted from the American Psychiatric Association Guidelines, 2010
Domain Indicator Standard






Assess need for treatment based on symptom-based
threshold (i.e., standard cut-off score on standardized
measure or clinical judgment of severity), not based on
patient request
Choice of treatment Base treatment choice on depression history (e.g., prior
treatments) and severity
Adjustment of starting dose
for interaction with ARVs
Adjust antidepressant starting dose to account for interaction
with antiretrovirals
Managing treatment First clinical follow-up after
treatment initiation
Within 2 weeks to assess tolerability, within 4 weeks to
assess efficacy
How effectiveness is assessed Systematic measure of symptoms
When to increase dose Increase dose based on formal assessment of tolerability
or efficacy
How high to increase dose Titrate up to full FDA-approved range until effect is achieved
When medication is changed Change medication based on formal assessment of
tolerability or efficacy, and only after adequate trial
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transcripts and selected representative quotes to summarize
the manifest content themes for each indicator. Dis-
crepancies in themes identified or quotes selected were
discussed by both raters until consensus was reached.
Finally, we used exploratory principal factor analysis13 to
assess whether the assigned scores for the nine best-
practices indicators could be combined into a single sum-
mary best-practices score. We replaced the small number of
missing values (0.9%–5 providers were each missing one of
nine items) with that participant’s mean score on the non-
missing items before calculating the summary (weighted
factor) score. An alternative approach of calculating a
summary score only from nonmissing items, with all non-
missing items weighted equally, yielded comparable results.
After confirming the appropriateness of creating the sum-
mary best-practices score and the approximately normal
distribution of the resulting scale, we used linear regression
models (with robust standard errors to account for cluster-




All eligible providers at the three sites (n = 72) were
approached and consented to participate in the study
(Table 3). About half of the providers (n = 38) were at-
tending-level medical doctors (MD), 24 were MD-fellows,
6 were nurse practitioners, and 4 were physician assis-
tants. The sample was fairly evenly split between male
and female providers, and the majority of participants
were Caucasian (78%). Providers had a median of 8 years
Table 2. Reported Provider Depression Treatment Practices
Indicator Response Assigned scorea n (%)
Assessment of depression - Uses standardized depression measure with all patients 5 10 (14%)
- Routinely asks all patients some screening question(s) 4 13 (18%)
- Asks only patients who exhibit signs of depression 3 37 (51%)
- Asks only when patients report depression or ask for
treatment
2 7 (10%)
- No method identified 1 5 (7%)
Assessment of need for
treatment
- Based on symptom-based threshold (i.e., standard cut-off
score on standardized measure or clinical judgment of
severity)
3 48 (67%)
- Treats only when patient asks 2 6 (8%)
- No method identified 1 18 (25%)
Choice of treatment - Clinical judgment based on depression history (e.g., prior
treatments) and severity
3 39 (54%)
- Patient asks for a specific treatment 2 0 (0%)
- No method identified 1 33 (46%)
Adjustment of starting dose
for interaction with ARVs
- Yes (adjusts starting dose based on ARV regimen) 2 26 (36%)
- No (does not adjust starting dose) 1 46 (64%)
First clinical follow-up after
treatment initiation
- Within 2 weeks 5 9 (13%)
- 2–4 weeks 4 17 (24%)
- 4–6 weeks 3 19 (27%)
- > 6 weeks 2 12 (17%)
- At next clinic visit (*3 months) 1 13 (19%)
How effectiveness is assessed - Measures symptoms systematically 4 6 (8%)
- Asks about symptoms 3 40 (56%)
- Patient reports symptoms 2 19 (26%)
- No method 1 7 (10%)
When medication is titrated - Increases dose based on formal assessment of tolerability
or efficacy
4 26 (36%)
- Increases dose based on informal assessment of depressive
signs and symptoms
3 18 (25%)
- Increases dose when patient asks 2 15 (21%)
- No method identified 1 13 (18%)
How high medication is
titrated
- Full titration (will use full FDA-approved range) 3 32 (45%)
- Some titration (will increase dose some but not use full
range)
2 34 (48%)
- No titration (will not increase dose) 1 5 (7%)
When medication is changed - Decision to change medication based on formal
assessment of tolerability or efficacy; changes only after
adequate trial
3 12 (17%)
- Decision to change based on tolerability or efficacy, but
not necessarily after an adequate trial
2 45 (64%)
- Never changes from initial medication 1 13 (19%)
aScores from highest (responses closest to best practices) to lowest (responses furthest from best practice).
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of experience treating HIV patients, and 35% had been
treating HIV patients for less than 5 years. On average,
providers reported that they devote approximately one-
third of their total professional effort to clinical work,
with three-quarters of their clinical effort dedicated to
HIV treatment.
Providers’ median estimate of the proportion of their HIV
caseload that was depressed was 30% (range: 10–80%; IQR:
20–50). Providers’ median estimate of the proportion of their
depressed HIV caseload that was receiving any depression
treatment was 50% (range: 10–100%; IQR: 40–71%). HIV
providers estimated that they were the primary source of
depression treatment for 50% (median) of their patients who
were receiving any depression treatment (range: 0–100%;
IQR: 20–80%).
Sixty percent of providers reported feeling very or ex-
tremely confident prescribing a first antidepressant, but only
14% were very or extremely confident going to second-line
treatment (changing or augmenting an antidepressant). Se-
venty-eight percent of providers were very or extremely
confident that treating depression was a part of their role, and
73% felt it was very or extremely appropriate to receive de-
cision support around prescribing antidepressants from
nonprescribing clinic personnel (e.g., social worker, psychol-
ogist, or nurse).
Depression treatment practices
Table 2 presents a quantitative summary of providers’
self-reported depression treatment practices relative to evi-
dence-based guidelines, and Table 4 presents representative
quotes from the qualitative content analysis of providers’
responses.
Assessing depression. National guidelines recommend
using a standardized measure to routinely assess all patients
for depression. Overall, 31% of providers reported that they
routinely assess patients for depression, with 12% using a
standardized measure, and 19% using their own questions or
observations. Content analysis indicated that providers pri-
marily relied upon patient self-report, signs, and symptom-
atology, such as poor eye contact, being emotionless or
disheveled, crying, slow speech, and change in weight. With a
patient the provider had known for many years, the provider
might recognize depression as soon as she entered the exam
room because of these signs and symptoms. These initial ob-
servations might lead the providers to follow up on more
nuanced symptoms of depression, including a change in ap-
petite, guilt, mood, anhedonia, insomnia, fatigue, and libido
dysfunction.
Few providers (12%) reported use of standardized mea-
sures or assessments. One provider reported using a
Table 3. Characteristics of Sample (n = 72)






MD attending 38 (52.7)
MD fellow 24 (33.3)
Nurse practitioner 6 (8.3)











Years treating HIV 8 (3–16) 0–30
0–4 25 (34.7)
5+ 47 (65.3)
Clinical effort as % of full professional effort 30% (20–50%) 10–100%
HIV clinical effort as % of all clinical effort 75% (40–90%) 5–100%
Perception of HIV patient caseload
Proportion that are depressed 30% (20–50%) 10–80%
Proportion of depressed that are being treated 50% (40–71%) 10–100%
Proportion of treated that are being treated by HIV provider 50% (20–80%) 0–100%
Very or extremely confident
Prescribing an initial antidepressant 42 (59.1)
Changing or augmenting antidepressants 10 (14.3)
Treating depression is part of role 55 (77.4)
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standardized measurement to determine the severity of de-
pression only after noticing signs and symptoms. Various
screening methods were mentioned. Among those identifying
any method, most referred to the ‘‘SIGECAPS’’ mnemonic
device (an acronym of the core symptoms of depression)
(n = 6), and the Patient Health Questionnaire-9 (n = 3).
While many providers acknowledged that screening in-
struments were the best way to assess depression, most pre-
ferred a ‘‘free-flowing’’ method to assess depression, starting
with general questions such as ‘‘How is your mood’’ or ‘‘How
is life?’’, leading to more specific questions such as ‘‘Are you
able to sleep well?,’’ ‘‘Has there been a change in your appe-
tite?,’’ ‘‘Are you able to concentrate at work?,’’ and ‘‘Do you
still enjoy social activities?’’
Need for treatment. National guidelines recommend that
the decision to treat a depressive illness should be informed
by the outcome of a standardized measure in conjunction
with clinical assessment of severity and related factors. Two-
thirds of providers reported using a clinical assessment of
severity, with or without a standardized measure, to deter-
mine need for treatment. Seven percent initiated treatment
only when asked by the patient, and 24% reported no sys-
tematic approach to determining need for treatment. Most
providers said that they would wait a few weeks before ini-
tiating treatment if patients reported situational depression
such as loss of a job, financial concerns, or death in family, or if
the provider felt the depression was mild or temporary. Some
providers also elicited patient input into a discussion about
depression treatment. Some patients would ask for treatment,
while others denied that they had depression. Most providers
said they always assessed patients’ willingness to take anti-
depressants, since many patients felt it was just ‘‘another pill
to take’’ and would increase medication and cost burden.
Choice of treatment. National guidelines recommend
that once need for treatment is determined, the specific
treatment plan (counseling, medication, or both) should be
informed by factors such as previous treatment experiences,
severity of symptoms, and patient preference. Approximately
half of providers reported that they consider such factors
when developing a depression treatment plan, whereas 44%
reported no systematic criteria. Although providers expressed
a preference for medication therapy, most were not opposed
Table 4. Representative Quotes Indicating Depression Treatment Practices
Indicators Quote
Identifying depression
Assessing depression ‘‘While I don’t do a formal standardized questionnaire for my patients, I think I
know the signs and symptoms to look out for, just by seeing people. Often
times I just rely on things like that to see if they’re depressed. And if I get that
hint that they might be depressed, I just ask more specific questions.’’
Initiating treatment
Need for treatment ‘‘. I think that if those symptoms are creating a change in the quality of life or
affecting their activities of daily living, or certainly if they’re impacting their
ability to cooperate and participate in their medical care. I think that’s an
indication for treatment.’’
‘‘. .I think depending on how severe their depression appears to be .’’
Choice of treatment ‘‘. it’s very patient driven. I mean, you can’t force a patient to do something,
so if they don’t want to take a medicine.then you can try the counseling
route. Some people say they don’t want to talk to anybody, and they’re
happier taking a pill. it’s almost completely guided by what the patient is
willing to do.’’
Adjust starting dose for interaction
with ARVs
‘‘. I will do like, I’ll check drug interactions. So that I can tell them what to
look out for, but I usually just start with the initial starting lowest dose. So
I’m pretty conservative.’’
Managing treatment
Follow-up after treatment initiation ‘‘. ideally it would be two weeks into it and again at four weeks, but I think in
reality maybe just at four weeks.’’
‘‘So I always try to schedule them back within a month and if they’re severely
depressed, maybe sooner. Whether or not they come back is a different issue,
but I do schedule them.’’
Assessing effectiveness ‘‘[I assess effectiveness] based on what they tell me, and what they look like
when they come back. You know, if their affect improved, do they look
brighter .’’
When to titrate ‘‘[Increase dose based on] inadequate resolution of symptoms, such as
depressed mood, interest in activities, still issues with functional impairment,
based on the depression. ..’’
How high to titrate ‘‘I just look in the standard Pharmacopoeia [which] usually gives you a max
dose and I will titrate up to that max dose. Every antidepressant is different
on that dose.’’
Changing antidepressants ‘‘I guess if they’re having an adverse effect on the first one I’ve tried, or it seems
like they’re not making progress and we’re getting to doses that I’m
uncomfortable with then we’ll switch.’’
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to psychotherapy. For mild depressive episodes, cognitive
behavioral therapy was often suggested before pharmaco-
logical management. Pharmacological management was
encouraged when symptoms began to interfere with the
patient’s quality of life, including work, relationships, sleep,
appetite, and health management. Many providers said they
would recommend a form of behavioral therapy in conjunc-
tion with or prior to prescribing medication. Providers also
described cost and previous treatment successes as guides for
antidepressant selection.
Adjusting starting dose to account for interactions with
ARVs. Due to the potential for some antiretrovirals to
increase circulating antidepressant levels, HIV-specific treat-
ment guidelines recommend using lower starting antide-
pressant doses. In our sample, one-third of providers reported
adjusting antidepressant starting doses to account for the
patient’s ARV regimen, while two-thirds did not. Responses
suggest that most providers were unaware of this recom-
mendation. However, some providers reported different ap-
proaches depending on the class of antidepressant. For
example, one provider stated, ‘‘generally I do not adjust if
prescribing an SSRI or [citalopram] because of the [low]
chance of.side effects.’’ Of the providers who reported that
they did adjust antidepressant starting doses, they did so by
referring to pharmaceutical reference texts or the pharmacist
on service.
Follow-up after treatment initiation. National guidelines
recommend that providers follow up with patients within 2
weeks of initiating an antidepressant regimen to assess for
increased suicidal thoughts and to address any side effects
that may have emerged, and within 4 weeks to assess re-
sponse to treatment. Fourteen percent of providers reported
scheduling phone or in-person follow-up with patients within
2 weeks of starting a new antidepressant regimen, and 38%
followed up within 4 weeks. Fifteen percent of providers did
not follow up until the next regularly scheduled clinic
appointment (normally every 3–6 months for HIV care). Pro-
viders reported considering the severity of the patient’s de-
pression, patient access to the clinic, and contact with mental
health providers when deciding on follow-up. Patients with
more severe depression were followed up sooner than patients
with milder depression. However, as one provider stated, ‘‘a
patient who is that depressed would probably be referred to a
mental health provider who has more skills and training to
treat the patient.’’ Despite in-person follow-up barriers, many
providers felt it was still important to offer support after initial
diagnosis. One provider stated ‘‘it’s important to let the patient
see you are emotionally invested in their well-being.’’
Assessing response. National guidelines recommend
measuring symptoms systematically to assess response.
About two-thirds of providers asked about symptoms in
some fashion to assess effectiveness, although few (9%) re-
ported using a standardized measure to do so. Most providers
reported starting the conversation with ‘‘How are you doing’’
or ‘‘How you are feeling?’’ In addition to patient feedback,
providers also mentioned reviewing the symptoms the pa-
tient had at initial presentation. Although providers often
referred to initial signs and symptoms, very few providers
said they actually used a measurement tool to compare to
baseline when assessing for response. Twenty-six percent re-
ported relying on the patient to report changes in symptoms
and whether the treatment is working. Seven percent had no
method to assess response.
When and how high to increase dose. National guide-
lines recommend systematic assessment of response and tol-
erability to guide antidepressant dose changes, with doses
being increased until full response is achieved, side effects
become unsupportable, or the maximum dose is reached.
Approximately two-thirds of providers reported increasing
doses based on formal or informal assessments of response
and/or tolerability, 22% increased doses when asked by the
patient, and 16% had no systematic criteria for dose adjust-
ment. One provider acknowledged being taught to measure
symptoms objectively but preferred informal discussion with
the patient. All providers who adjusted doses said they
waited at least 4–6 weeks before increasing a dose. At follow-
up, providers normally reviewed the symptoms the patient
had at onset; if the symptoms were still present and side ef-
fects were tolerable then a provider would increase the dose.
One provider stated, ‘‘It’s based on whether the patient has
had an adverse response.If they have some [positive] re-
sponse then I think that’s a good sign to increase the amount.’’
About half of the providers (48%) said they would titrate to
the maximum recommended dose if needed, with guidance
from product literature or pharmaceutical texts. Forty-five
percent said they would not titrate up to the maximum dose,
and 7% reported never increasing from a starting dose.
Changing antidepressants. According to national guide-
lines, before changing to a new antidepressant, the original
antidepressant should be given a trial of adequate duration
(6–8 weeks) and dose (moderate to high dose) unless the
patient develops side effects that cannot be satisfactorily
addressed. Eighty-two percent of providers reported consid-
ering response and/or tolerability when considering switch-
ing the depression treatment plan, but only 18% ensured that
the original antidepressant had been given an adequate trial.
The most common reasons that providers offered for chang-
ing an antidepressant was if it ‘‘did not work’’ (duration and
dose unspecified) or the patient was not tolerating the medi-
cation. Only 18% described ensuring an adequate trial of an
antidepressant before switching to a different medication.
Most providers reported feeling comfortable managing one
medication switch, but subsequently preferred to refer to
someone with more specific expertise.
Difference by years of clinical experience
For several practice guidelines, greater adherence was re-
ported by providers with < 5 years of experience than by
those with ‡ 5 years of experience, although most differences
were not statistically significant in this small sample. Practice
guidelines with at least a 10 percentage point difference in-
dicating greater reported adherence among those with < 5
years of clinical experience included following up within two
weeks of initial prescription (20% vs. 9%, p = 0.14), measuring
symptoms systematically to assess efficacy (20% vs. 2%,
p = 0.13), basing dose adjustment decisions on assessment of
response and tolerability (44% vs. 32%, p = 0.4), using the full
FDA dosing range (54% vs. 40%, p = 0.49), and ensuring an
adequate trial before switching (29% vs. 11%, p < 0.01).
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An exploratory factor analysis of the nine indicators of
depression treatment practice supported a single factor solu-
tion (eigenvalue for first factor: 1.83; eigenvalue for second
factor: 0.50), with eight of nine items positively weighted on
the first factor. The exception was adjustment of antidepres-
sant starting doses to account for ARV interactions, which had
a near-null weight on both the first and second factors. We
therefore calculated a ‘‘summary best-practices score’’ of de-
pression treatment using the estimated factor loadings on the
eight positively weighted indicators and rescaled the result-
ing score to range from 0–10.
Those with < 5 years of experience had a higher summary
best practices score than those with ‡ 5 years of experience
(6.6 vs. 5.0 on a 0–10 scale, p = 0.05) (Fig. 1). A similar pattern
emerged when comparing MD-fellows and MD-attendings,
with a higher proportion of MD-fellows reporting adherence
to best-practices guidelines for a number of indicators and
MD-fellows having a higher summary best practices score
(6.5 vs. 5.4, p = 0.21). Midlevel providers (NPs and PAs) had a
lower summary best-practices score than either attendings or
fellows, although the number of midlevels in this sample was
small. Summary scores did not differ by site (site-specific
means of 5.7, 5.5, and 5.5, p = 0.97).
Discussion
Very few data exist on the practices of nonmental health
providers in treating depression. There is a growing litera-
ture on the high prevalence and negative consequences of
co-morbid depression in HIV1,4,14 as well as other chronic
illnesses such as heart disease15,16 and diabetes,17,18 sug-
gestive evidence that treating depression may improve HIV
adherence and outcomes,19 and a growing recognition that
existing mental health resources are inadequate to meet the
needs of these populations. Recent initiatives have sought to
integrate depression treatment with primary care and
chronic disease management,8,20–22 and promising models
exist for the provision of mental health care for HIV-infected
patients,9,23 yet gaps remain in mental health care coverage
and access.20
In this sample of 72 HIV providers at three academic
medical centers, providers demonstrated an appreciation of
the significant burden of depression in patients presenting for
HIV care. Providers’ estimates of depression prevalence in
their caseload were fairly close to estimates of depression
prevalence in HIV patients nationally24 as well as at these
specific clinics.25–27 Providers’ estimates that approximately
half of their depressed patients were receiving treatment were
also quite close to national estimates suggesting that about
half of those with depression are not being treated.3,24,28
Although variability was evident in providers’ approaches
to identifying depression and developing and implementing a
treatment plan, all providers were taking steps to address
depression either by referral or treatment initiation. In gen-
eral, reported practices of these providers follow the spirit
if not every detail of best practices and practice guidelines:
assess symptoms, prescribe treatment, monitor improve-
ment, adjust treatment if response is not adequate, and refer
when appropriate. However, specific discrepancies be-
tween guidelines and reported practices were apparent. Im-
portantly, these discrepancies are readily addressable with
education and support.
National guidelines recommend that all patients be
screened on a routine basis utilizing a validated measure of
symptomatology.10 In general, the providers in this study
responded to symptoms that were obvious during the patient
encounter, but few providers endorsed using a standard
measure when depression was suspected, and few providers
reported screening all patients regardless of signs of depres-
sion. Extensive evidence suggests that as many as half of de-
pressive illnesses go unrecognized in primary and
nonpsychiatric specialty care in the absence of screening,3,28
with subsequent failure to address the depression and miti-
gate its impact on chronic disease management.
Depression screening alone is not sufficient to improve
outcomes.29,30 It is only the first in a critical series of steps to
successfully treat depression. Initiation of treatment is a nec-
essary next step. When initiating treatment, the providers in
this study largely relied on clinical judgment and patient
preference. This approach is directly in line with best practices
FIG. 1. Depression treatment practices
summary score by provider years of experi-
ence and level of clinical training.
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that identify patient preference and clinical severity as key
determinants in whether to initiate psychotherapy or medi-
cation. A small minority of providers preferred immediate
referral to a mental health professional, an option necessarily
limited by resources and access. While most providers were
comfortable prescribing an initial antidepressant, the majority
were unaware of recommendations to adjust antidepressant
starting doses based on a patient’s ARV regimen.
Follow-up and monitoring of depression treatment is often
limited by the realities of busy clinic settings. Contact within 2
weeks of initiating antidepressant medication is a target
challenging to meet in any busy clinic. STAR*D, IMPACT,
and other trials of collaborative care approaches have dem-
onstrated that support staff can successfully assist the pro-
vider in meeting this goal.7,20,21 Care managers who can use
validated instruments to assess systematically suicidality,
treatment-emergent side effects, and treatment response can
provide critical input while minimizing provider burden.
Timely and brief communication between care manager and
provider has intuitive value to meet the treatment and time
needs of patients and providers while aligning practices with
national guidelines.
Care managers can also provide guidance in decisions
around a second treatment approach (e.g., switching or aug-
menting medications) if an adequate trial of the first treatment
approach is not successful. Indeed, data from STAR*D sug-
gest that only one-third of depressed patients are likely to
respond to the first adequate trial, although two-thirds are
likely to achieve remission within two or three carefully
monitored adequate trials.31 Providers in this study were
generally comfortable initiating one antidepressant but
markedly less comfortable with switching or augmenting
antidepressants.
Even with such care manager support, it is unreasonable to
expect that nonmental health providers will be able to meet
the needs of all depressed patients in their care. In the STAR*D
trial, one-third of patients with depression did not achieve
remission after up to three carefully monitored adequate
treatment trials.31 Trained and supported care managers can
help providers efficiently differentiate between patients
whose depression can likely be successfully addressed in their
care and patients whose presentations suggest immediate
referral, such as those with prior depression treatment resis-
tance, complicating psychiatric co-morbidity (e.g., mania or
psychosis), or serious suicidality.
In this sample, providers who had been treating HIV pa-
tients for < 5 years were more likely to report best-practice
principles of depression treatment and, on average, had
higher best-practice summary scores than providers who had
been treating HIV patients for 5 years or more. Similarly, MD-
fellows reported higher concordance with best practices than
MD-attendings. This finding may reflect closer proximity to
general medical training including depression management
during medical school and residency, or it may reflect recent
shifts in medical curricula toward broader integration of
training in depression treatment and specifically measure-
ment-based depression management.
This study makes a unique contribution to the literature on
the treatment of depression in HIV patients, providing a de-
tailed comparison of HIV providers’ self-reported depression
identification and treatment practices to national evidence-
based guidelines. While research has highlighted the gap
between depression prevalence and treatment among HIV
patients,3,24,32 we identified no other published studies that
detail HIV providers’ standard approaches to depression
screening, treatment choice, antidepressant initiation, assess-
ment of efficacy, dose adjustment, and treatment switches in
the context of routine HIV clinical care.
Interpretation of this study’s results is limited by the fact
that practices were measured by provider self-report, and that
provider reports were not verified through medical record
review. Social desirability may have influenced providers to
give optimistic assessments of their actual treatment practices.
This may result in an overestimation of the concordance of
providers’ practices with evidence-based guidelines. Further
research would benefit from assessing actual practices as re-
flected in observations or medical records. In terms of external
validity, the three sites involved are all in the U.S. Southeast,
in mid-sized population centers with large rural catchment
areas, and at academic institutions. Generalizability is limited
due to regional differences in practice realities (e.g., avail-
ability of mental health professionals with subsequent greater
or lesser involvement of HIV providers in depression man-
agement). Even within sites, variability was high with regard
to access to mental health care. In-clinic or on-site mental
health referral services varied by site as did payer mix (i.e.,
state-provided insurance, private insurance, self-pay). These
differences could affect attitudes and practices, for example,
as providers might provide greater depression care at clinics
where services were less readily available or where payer mix
did not favor easy referral to specialty care. In summary, HIV
providers in the present study demonstrated a clear under-
standing of the importance of depression in their patients.
Most providers were managing depression in at least some of
their patients, but their adherence to best-practices treatment
as described in national guidelines was variable. While all
providers receive some training in management of depres-
sion, HIV providers are not trained or expected to provide a
full spectrum of psychiatric care. However, the present study
suggests three reasonable targets for improvement that could
bring depression treatment practices by HIV providers closer
to national guidelines. The first is clinical or structural support
of routine screening for depression to address the large pro-
portion of cases that go unrecognized in medical care. The
second target is education of providers in a few key areas of
depression management: adjusting antidepressant doses to
account for interactions with antiretrovirals, measuring
treatment response systematically, and ensuring an adequate
trial of a given medication before switching or referring. The
third is support from care managers to assist with the more
time-intensive or complex aspects of depression treatment,
including regular monitoring of side effects and response.
Models of collaborative care and measurement-based care
have successfully addressed these gaps in research settings in
both primary and specialty medical care.7,20,21 Efforts to im-
plement these models in more widespread clinical practice
could pay large dividends for a modest investment in terms of
increasing the quality of depression care and improving
mental health and HIV outcomes.
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